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Abstract
Background: Multiple Sclerosis (MS) is an incurable, chronic, potentially progressive and unpredictable disease of the
central nervous system. The disease produces a range of unpleasant and debilitating symptoms, which can have a
profound impact including disrupting activities of daily living, employment, income, relationships, social and leisure
activities, and life goals. Adjusting to the illness is therefore particularly challenging. This trial tests the effectiveness of a
Cognitive Behavioural intervention compared to Supportive Listening to assist adjustment in the early stages of MS.
Methods/Design: This is a two arm randomized multi-centre parallel group controlled trial. 122 consenting participants
who meet eligibility criteria will be randomly allocated to receive either Cognitive Behavioral Therapy or Supportive
Listening. Eight one hour sessions of therapy (delivered over a period of 10 weeks) will be delivered by general nurses
trained in both treatments. Self-report questionnaire data will be collected at baseline (0 weeks), mid-therapy (week 5
of therapy), post-therapy (15 weeks) and at six months (26 weeks) and twelve months (52 weeks) follow-up. Primary
outcomes are distress and MS-related social and role impairment at twelve month follow-up. Analysis will also consider
predictors and mechanisms of change during therapy. In-depth interviews to examine participants' experiences of the
interventions will be conducted with a purposively sampled sub-set of the trial participants. An economic analysis will
also take place.
Discussion: This trial is distinctive in its aims in that it aids adjustment to MS in a broad sense. It is not a treatment
specifically for depression. Use of nurses as therapists makes the interventions potentially viable in terms of being rolled
out in the NHS. The trial benefits from incorporating patient input in the development and evaluation stages. The trial
will provide important information about the efficacy, cost-effectiveness and acceptability of the interventions as well as
mechanisms of psychosocial adjustment.
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Background
Psychological adjustment to Multiple Sclerosis
Multiple Sclerosis (MS) is an incurable, chronic and
unpredictable disease of the central nervous system. The
disease is characterized by the destruction of the myelin
sheath surrounding the nerves resulting in the formation
of plaques. These plaques disrupt the transmission of
nerve impulses leading to the symptoms of the illness
which include, but are not limited to, spasticity, loss of
balance and co-ordination, blurred or double vision,
blindness, numbness, speech distortions, bladder and
bowel problems, fatigue, pain and cognitive dysfunction
[1]. Plaques can occur in a variety of sites resulting in sub-
stantial variation in the type and nature of the symptoms
across individuals. The course of the illness is also highly
variable and unpredictable [1]. The majority have either a
relapsing-remitting or a relapsing-progressive course.
Patients experience periods of partial or total remission
where the illness is inactive, interspersed with symptom
relapses. MS can also have a chronic-progressive course, in
which there is a progressive worsening of symptoms and
disability. Patients may be initially diagnosed with one
type of MS, but over time progress to another.
MS is thought to affect more than 2.5 million people
worldwide and around 400,000 people in the United
States and 85,000 people in the United Kingdom cur-
rently live with the disease [2,3]. The illness is more com-
mon in females than males. The cause of the illness is
largely unknown and there is currently no cure. Treatment
focuses on the management of the patient's symptoms
and reducing the number and severity of relapses.
Individuals who have MS are faced with uncertainty about
the future, unpleasant and unpredictable symptoms,
treatment regimes and drug side effects. MS can have pro-
found consequences including disruptions to life goals,
employment, income, relationships, social and leisure
activities and activities of daily living. Therefore it is not
surprising that it poses multiple challenges for psycholog-
ical adjustment. A large body of empirical literature attests
to poor adjustment outcomes in MS including elevated
rates of depressive symptomology or distress [4-7],
increased anxiety [5,8], poor subjective well-being and
quality of life [5,9], and social role and relationship diffi-
culties [4,10]. On the other hand, research and clinical
experience suggests that a substantial proportion of peo-
ple with MS manage to adapt well to living with the illness
[11,12].
Illness factors such as the extent of neurological disability,
symptom severity, remission status and length of illness
can influence levels of adjustment or a sense of well-being
and quality of life [13,14]. However, psychological factors
can be as important in predicting and explaining individ-
ual differences in adjustment [14,15]. A systematic review
conducted as pilot work for this trial demonstrated that a
range of psychological factors were associated with adjust-
ment outcomes in MS [16]. For instance, people reporting
high levels of perceived social support showed better
adjustment [17,18], as did individuals with high levels of
optimism and hope [19,20] and those who engaged in
health behaviours such as exercise [21]. Use of problem-
focussed coping strategies such as planning was also con-
sistently associated with more positive outcomes. On the
other hand, emotion-focussed coping strategies including
wishful thinking and escape/avoidance were consistently
linked with worse adjustment [22,23]. High perceived lev-
els of stress were also linked to worse adjustment [23].
Similarly, a tendency to interpret events, the illness and
MS symptoms in an overly negative fashion has been
linked to worse adjustment [24-26]. Since many of these
factors are potentially modifiable through psychological
intervention there is reason to conclude that a programme
of therapy that addresses a number of these factors may
lead to improvements in adjustment.
In the intervention literature to date targets of psycholog-
ical interventions for people with MS, particularly Cogni-
tive Behavioral Therapy (CBT), have been mostly centred
on the alleviation of depression [27-29]. Two systematic
reviews of psychological interventions for MS suggest that
there is some evidence that cognitive behavioural
approaches can be beneficial in the treatment of depres-
sion, and in helping people to adjust to, and cope with
having MS[15,30] However, both reviews also criticise the
methodological quality of the intervention studies to
date. Many have small sample sizes and many inade-
quately report details of their intervention and trial meth-
odology. This makes it hard to draw definitive
conclusions about the efficacy of CBT in this area. Both
reviews conclude that further, well-designed trials of CBT-
based approaches are warranted. One in particular, con-
cludes that existing research on adjustment and coping
looks encouraging and that approaches that target the
time period soon after diagnosis and see adjustment as an
ongoing process would be useful [15]. This review also
draws particular attention to the importance of following
the CONSORT statement [31] for reporting such trials and
using manuals to make replication of interventions possi-
ble.
Background to the project
Given the evidence that CBT is helpful in improving men-
tal health and psychological aspects of chronic health
conditions, we wanted to investigate the efficacy of CBT in
helping people with MS adjust to the psychological and
social challenges of living with the disease. Although there
are some differences between regional MS services in the
United Kingdom in availability of information, adviceBMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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and support in the early stages of MS, formal psychologi-
cal interventions are not routinely available.
The aim of this project is to assess whether CBT can
enhance the adjustment of people in the relatively early
years of dealing with MS. Unlike most previous studies
which have evaluated the use of CBT in this group [15,30],
the focus of this study is to improve broadly defined
adjustment outcomes rather than restricting the scope of
the intervention to reducing psychiatric morbidity in MS
populations where individuals meet criteria for psychiat-
ric disorder. By focusing the intervention on the earlier
years of MS it is hoped that patients will learn strategies
that will assist in managing the illness in the future.
Because most MS patients receive little structured psycho-
logical support, CBT will be compared to Supportive Lis-
tening therapy rather than treatment as usual. This will
allow us to ascertain whether there are any particular ben-
efits to CBT or whether just having the opportunity to talk
to a supportive, empathetic therapist can make a differ-
ence to adjustment outcomes. In line with suggestions for
research in this area, general nurses will be trained and
supervised to deliver the interventions [15].
Aims
Primary Aim
1) To determine whether patients with early stage MS who
undertake an 8 session CBT programme for adjustment to
MS will demonstrate better adjustment (defined as psy-
chological well-being and social and role adjustment)
than those undergoing 8 sessions of Supportive Listening
(SL).
Secondary Aims
2) To examine whether the CBT and SL groups differ on a
range of secondary outcomes including quality of life,
acceptance of illness and dysfunctional cognitions.
3) To examine whether changes in predefined psycholog-
ical mechanisms act as mediators through which change/
adjustment in our primary outcomes occurs. These pro-
posed mediating factors are dysfunctional or unhelpful
cognitions and behaviours, and acceptance of illness.
4) To examine whether patients' responses to treatment is
moderated by therapeutic alliance factors, patients' treat-
ment preference, engagement in homework tasks, and
perceived social support.
5) To examine the cost-effectiveness of both interventions
by taking into account benefits to patients, effects on
health service usage and other costs to society, and cost of
providing the interventions.
6) To evaluate both interventions from the perspective of
the person with MS using in-depth interviews and qualita-
tive analysis methods to elicit their experiences of the ther-
apy, any changes it brought, and any helpful and
unhelpful aspects.
Methods/Design
Design
The trial is a two arm randomized multi-centre parallel
group controlled trial. Consenting participants who meet
eligibility criteria are randomly allocated to receive either
CBT for adjustment to MS or Supportive Listening (SL).
The SL arm of the trial has been chosen over standard
medical care as a comparison condition as it is an accept-
able and plausible approach that will control for non-spe-
cific treatment factors such as support, therapist time and
attention, and patient expectations of improvement. The
full trial design is summarized in Figure 1.
Setting
The trial has two centers (Southampton and South Lon-
don) and each center has one therapist who delivers both
CBT and SL.
Ethical approval
This study has been reviewed and approved by the
Thames Valley Multi-centre Research Ethics Committee
(ref: 07/MRE12/6)
Participants
Sample size calculation
Since there were no available MS CBT trials using either of
our primary outcomes we computed a power analysis cal-
culation based on a recent CBT trial for depression in peo-
ple with MS, which used the Beck Depression Inventory
(BDI) as the primary outcome [28]. The BDI, like the
GHQ (one of our primary outcomes) is a measure of affec-
tive distress. Using a conservative estimate for the within-
group standard deviation the effect size from this study
was .60. To achieve 80% power at alpha = 0.025 signifi-
cance level (to adjust for two primary outcomes) we
would need 55 patients in each group to detect an effect
of this magnitude by an independent samples t-test. To
allow for attrition of around 10% at follow-up we need to
initially include 61 participants in each group. In our CBT
for MS fatigue trial we only lost 3/72 patients to follow-up
(4%).
Eligibility criteria
Inclusion criteria
Participants do not need to be currently experiencing dis-
tress, depression or any particular coping difficulties to be
included in the study. However, they must:BMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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CONSORT flowchart of trial design Figure 1
CONSORT flowchart of trial design.
Screened for eligibility 
Baseline assessment
(0 weeks)  
Excluded  
1. Not meeting inclusion criteria 
2. Refused to participate 
3. Other reasons  
Not randomized 
1. Not meeting eligibility criteria  
2. Refused to participate  
3. Other reasons 
Randomized 
(n=122) 
Allocation 
Completed 
therapy
Dropped out 
of therapy
Cognitive Behavior Therapy 
Delivered over 10 weeks 
Dropped out 
of therapy
Supportive Listening  
Delivered over 10 weeks 
Assessed 
5 weeks  
Assessed 
15 weeks 
Assessed 
5 weeks  
Assessed 
5 weeks 
Assessed
5 weeks  
Assessed 
15 weeks 
Assessed 
15 weeks 
Assessed 
15 weeks 
Assessed
26 weeks 
Assessed 
52 weeks
Assessed
26 weeks 
Assessed 
52 weeks
Assessed
26 weeks 
Assessed 
52 weeks 
Mid-therapy 
assessment  
6 month 
follow-up  
Post-therapy 
assessment  
Assessed
26 weeks 
Allocated to either London centre
(i.e. Nurse-therapist 1) or 
Southampton centre (i.e. Nurse-
therapist 2) 
Allocated to either London centre
(i.e. Nurse-therapist 1) or 
Southampton centre (i.e. Nurse-
therapist 2) 
Completed
therapy
Allocation: 
therapists  
Allocation: 
patients  
Assessed 
52 weeks
Enrolment 
12 month 
follow-up 
Analyzed Analyzed Analyzed Analyzed
Data 
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- have a definite diagnosis of MS, of any type, con-
firmed by a neurologist.
- be diagnosed with MS within the last 10 years.
- have some degree of ambulation (with assistance if
needed), equivalent to an Expanded Disability Status
Scale (EDSS) score [32] of 6.5 or less.
- be stabilised on disease modifying or anti-depressant
medication (if taking). For disease modifying drugs
(e.g. interferon) patients must have been on medica-
tion for a minimum of 3 months. For anti-depressants,
patients must be on a stable dose for a minimum of 2
months.
Exclusion criteria
Patients will be excluded from the study if they:
- have gross cognitive impairment that would make
participation in 8 one hour sessions of talking therapy
problematic or distressing. This will be assessed using
the Telephone Interview for Cognitive Status-Modi-
fied; TICS-M [33] administered by the trial co-ordina-
tor during screening. Patients with a score of less than
20 will be excluded.
- have serious psychological disorders for which treat-
ment would be inappropriate (including psychotic
disorders or active substance abuse problems).
- have other co-morbid serious chronic illnesses (e.g. a
malignancy).
- are currently participating in other psychological
therapies or have participated in other therapies
within the last 2 months.
- are considered by their treating physician to have
needs that are more appropriately addressed by a refer-
ral to another psychological service (e.g. psychiatrist,
clinical psychologist, MS special mental health nurse).
Source of participants
Participants will be recruited from two National Health
Service (NHS) MS centers in the Southampton area
(Southampton University Hospital Trust; SUHT) and
South London (King's College Hospital Trust; KCHT).
Recruitment and consent process
Patients seen or in contact with these services during the
trial period will be informed about the trial if they appear
to meet eligibility criteria. During routine consultations,
either one of the MS nurses or one of the neurologists will
use an eligibility checklist, detailing the key inclusion and
exclusion criteria, to identify suitable patients. The nurse/
neurologist will hand over a Participant Information
Sheet with a contact details reply slip, consent form, and
freepost envelope to all that are potentially eligible and
interested. If the participant is keen to be involved the
nurse/neurologist will ask permission to write down the
participant's contact details and freepost it back to the trial
co-ordinator so that she can contact them about the
project. Alternatively the patient can choose to initiate
contact with the research team by posting the contact
details form back to the trial co-ordinator, or getting in
touch by telephone or email.
Once contact is made with the trial co-ordinator the
patient's questions will be answered and their under-
standing of what is involved in the trial verified. Consent
forms will be returned to the trial co-ordinator by freepost
for those who wish to take part. On the form, participants
are given the choice to consent to the therapy trial and
questionnaire assessments only, or to an additional in-
depth telephone interview after their therapy programme
has been completed.
Eligibility screening and enrolment
After obtaining written consent, participants will be
screened for eligibility. Screening will be completed by the
trial co-ordinator over the telephone using a screening
checklist of the inclusion/exclusion criteria.
If potential participants do not meet the medication or
current/recent psychological therapy criteria at the time of
the eligibility screening they will be placed on hold and
there will be the necessary delay (see inclusion/exclusion
criteria) before they are enrolled into the trial. After
screening, participants will be notified on the telephone
by the trial co-ordinator whether they are eligible or inel-
igible for the trial.
Baseline questionnaire assessments
Eligible participants will be sent the baseline question-
naire and freepost return envelope together with a copy of
their consent form. The schedule of assessments in the
baseline questionnaire and subsequent follow-up ques-
tionnaires is outlined in Table 1.
Randomization
Randomization is at the patient level and will take place
after the baseline questionnaire has been received. The
randomization will be stratified by centre to ensure equal
proportions in each treatment arm. Randomization is
block stratified with varying block sizes. Randomization
will be handled by an independent service at the King's
College Mental Health and Neuroscience Clinical Trials
Unit (CTU). On receipt of the baseline questionnaire, the
trial co-ordinator will electronically submit details of eachB
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Table 1: Details and schedule of saMS trial assessment procedures
Measures administered Baseline 
(week 0)
Mid-therapy 
(week 5)
Post-therapy 
(week 15)
6 month follow-up 
(week 26)
12 month follow-up 
(week 52)
Demographics X - - - -
Detailed MS questions-(date of diagnosis, time since symptoms started, type of 
MS, recent and current relapses, treatment for depression, supplements or 
alternative therapies, participation in MS organizations)
X- -- -
Brief MS questions (recent changes in medication, interventions, recent and 
current relapses)
-- X X X
Expectations/preferences for therapy X - - - -
Global improvement and satisfaction ratings - - X - -
Feedback on CBT manual/strategies - - X - -
Continuation of use of CBT - - - X X
General Health Questionnaire (GHQ-12 [41]) X X X X X
Work and Social Adjustment Scale (WSAS [43]) X X X X X
Beliefs about Emotions Scale 
(BES; Rimes & Chalder; in preparation)
XX XX X
Significant Others Scale (SOS [49]) X - X X X
Acceptance of Chronic Health Conditions Scale (ACHC [45]) X X X X X
Psychological Vulnerability Scale (PVS [46]) X X X X X
Brief Illness Perception Questionnaire (B-IPQ [48]) X X X X X
Cognitive and Behavioural Responses to Symptoms Questionnaire (CBRSQ; 
Moss-Morris, Chalder, Skerrett & Baldwin, in preparation)
XX XX X
Client Service Receipt Inventory (CSRI [51]) X - - X X
EuroQoL (EQ5D [44]) X - - X X
Self-report Expanded Disability Status Scale (EDSS [50]) X - - - XBMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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participant to an electronic randomization system set up
and maintained by the CTU. The system then notifies the
relevant nurse-therapist (i.e. London or Southampton) of
the randomisation outcome by email immediately. This
email will be printed and placed on the participant's ther-
apy file.
Booking in participants
On receiving the randomisation outcome from the CTU
the nurse-therapist will contact the new participant, notify
them of their group allocation and set a date for their first
session. Nurse-therapists will endeavour to book patients
within one week of randomisation. Participants will be
consulted about special considerations needed for their
visit (e.g. disabled parking) and reimbursed for their
travel expenses.
Therapist training
The therapists in this trial are two general nurses without
prior experience in delivering psychological interventions,
or specialist MS experience. They were given 2 weeks of
intensive classroom training in understanding MS, CBT
and SL.
The training included a combination of didactic teaching,
homework readings, and discussion. Role play and vid-
eoed therapy sessions were also used throughout the CBT
and SL training sessions. A summary of the classroom
training package is presented in Table 2.
The classroom training was followed by 12 weeks of
closely supervised practice with 5 pilot patients. Each
nurse saw 3 pilot patients for 8 weeks of CBT and 2 pilot
patients for 8 weeks of Supportive Listening. These
patients had a diagnosis of MS but did not necessarily
meet other trial criteria. RMM supervised the SL and TC
and SR supervised the CBT.
Supervision of pilot patients occurred once a week as soon
after a session as possible. The supervisor listened to one
of the recent sessions and rated the session using the Ther-
apy Competence and Fidelity Rating scale modified spe-
cifically for this trial [34] This scale includes 14 items, 7 of
which assess SL and 7 CBT. Example items are 'Does the
therapist reflect or paraphrase appropriately' (SL) and
'Does the therapist help the client to identify specific types
of cognitive distortions or errors (e.g. all-or-nothing
thinking, over-generalization) (CBT item). The nurse-
therapist also listened to the session and completed self-
ratings of competence using the same rating scale. Super-
visor and nurse ratings were discussed during supervision
and strengths highlighted. Areas for improvements and
strategies for these were also identified. Checks were made
for treatment fidelity and to assess that CBT techniques
were not used in the SL sessions. Approximately midway
in the pilot phase of the training, both supervisors and
nurses met to discuss pilot patients and any difficulties
encountered. Difficult situations were role played and
new skills or ways of managing the situations were prac-
ticed.
Establishing Therapist competence
During the pilot/training stage the nurse-therapists audio-
taped every therapy session using digital recorders. The
clinical supervisors rated two randomly selected record-
ings (sessions 5, 6, 7 or 8) using the Therapy Competence
and Fidelity Rating scale described above. The therapists
were required to score at least 4 (i.e. a 'acceptable-good'
level of competence demonstrated) on all the relevant
items in order to be deemed competent in the therapy and
ready to commence therapy with trial participants.
Trial interventions
Both therapies will be delivered in 8 sessions over a 10
week period. The first six sessions will be scheduled
weekly and the last two fortnightly. The first session will
be 80–90 minutes long and the remainder will be
between 50 minutes to one hour. The first and fourth ses-
sions will be held face-to-face and the remaining six will
be telephone sessions. Telephone sessions make CBT
more accessible to patients, particularly those with mobil-
ity problems, and have been shown to be an effective form
of therapy for people with MS [27].
Both interventions will be carried out in accordance with
written, structured manuals. Participants will be issued
either a CBT or SL therapy manual in their first session
with the nurse-therapist.
CBT
Development of the manual and therapy package
Beck's cognitive model of emotion which incorporates a
developmental perspective [35] in conjunction with a sys-
tematic review of 72 studies which looked at psychologi-
cal factors associated with adjustment in MS [16] was used
to guide the development of the CBT model and therapy
manual for this trial. Details of our CBT model of adjust-
ment to MS are presented in the review [16]. Because
acceptance of MS appeared to be a significant factor in
adjusting to the illness, we incorporated some basic prin-
ciples for facilitating acceptance into our manual from
Steven Hayes' Acceptance and Commitment Therapy [36].
We also conducted two qualitative studies where 30 peo-
ple with early stage MS and 15 of their partners engaged
in in-depth interviews about their experiences of having
MS, problems they encountered, and the things they
found helpful and unhelpful in adjusting to living with
MS [[37]; Dennison, Yardley, Devereux and Moss-Morris,
in preparation]. Transcripts of these interviews were ana-BMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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lysed using thematic analysis. Core themes were covered
in the manual and verbatim quotes from the interviews
were used for illustrating points.
Once the 100 page draft manual was developed, it was
reviewed by people with MS and their families, neurolo-
gists, MS nurses and CBT therapists. Feedback from these
sources was then used to make appropriate amendments
to the manual.
We also developed a short 10 page booklet for the partic-
ipant to give to a partner or significant other entitled
"Coping when somebody close to you has MS". This
booklet covers information which closely reflects the
themes from the qualitative study on spouses of people
with MS [37]. These include dealing with feelings of help-
lessness and difficult emotions, how to support someone
with MS, dealing with other people's reactions to MS,
maintaining a social life in the face of MS, and finding a
balance between looking after your own well-being and
the needs of your partner with MS.
The CBT therapy package
The aim of this CBT package is to enable patients to adapt
appropriately to their illness. The focus is to achieve opti-
mal day-to-day functioning within the constraints of the
disease, to minimize distress and manage symptoms in
the short and long term. The treatment is structured but
also individualized to the needs of the patient as it is clear
from the literature and our qualitative interviews that the
process of adjustment can vary across individuals.
In the early sessions, participants will work with their
nurse-therapist in developing a formulation of their par-
ticular areas of strengths and difficulties. The manual con-
sists of nine chapters which can be used as appropriate
depending on the formulation (see Table 3 for details of
the manualized sessions). The nurse-therapist will work
Table 2: Details of the two week classroom training program for the nurse-therapists
Pragmatics of the trial and house keeping (6 hours) • Line management and orientation to the units
￿ Record keeping for the trial, general paperwork, keeping patient notes and writing 
GP letters
Understanding MS: (6.5 hours) ￿ Introduction to MS including the pathogenesis of the disease, types of MS, symptoms 
and medical treatment
￿ Understanding adjustment to MS and introduction to the CBT model and manual
￿ The role of partners and family members
Cognitive Behavioral Therapy (32.5 hours) ￿ Introduction to Beck's systems model of CBT
￿ Introduction to CBT, psychological therapies, and psychiatric diagnosis
￿ Process of treatment and how change takes place over time
￿ Assessment, conceptualization and formulation in CBT
￿ Supervision and how to use it
￿ Exploring the nurse-therapists' personal beliefs and assumptions
￿ Motivational Interviewing Skills
￿ Setting homework
￿ Overview of anxiety and depression, including prevalence and diagnostic criteria.
￿ Emotional processing and how to facilitate it.
￿ Psychiatric emergencies and risk assessment
￿ Identifying MS specific cognitions
￿ How to use thought records to link, thoughts, behaviors and emotions
￿ Challenging unhelpful thoughts
￿ How to deal with patients "realistic" negative thoughts
￿ Behavioral Activation and behavioral experiments
￿ Problem solving
￿ Dealing with resistance
￿ Dealing with hopelessness
Supportive Listening (13 hours) ￿ Introduction to therapist and patient manuals
￿ Issues around housekeeping
￿ Introduction to concepts of unconditional regard, warmth and empathy
￿ Describing the active listening techniques
￿ Facilitator demonstration of techniques
￿ Nurse role play using MS case studies
￿ Nurse role play using a personally relevant difficult or painful situation
￿ Practice and feedback using the variety of techniquesBMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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together with the participant in deciding which areas to
focus on and in setting tasks or homework to do in
between the sessions. The nurses will record which of the
nine chapters are covered in each session for each patient.
Both nurses and patients will work from the same detailed
manual.
Supportive Listening
Supportive Listening (SL) will be presented to patients as
a treatment based on the idea that they will be able to help
themselves if given the opportunity to talk freely, exten-
sively and confidentially about their experiences,
thoughts and feeling about MS and its effect on their lives.
If participants prefer not to focus on their MS, they will be
encouraged to choose other topics to talk about which,
they feel, are currently relevant to them.
The SL therapist manual is based on manuals used in pre-
vious trials comparing CBT to counselling [38] and prag-
matic rehabilitation to Supportive Listening therapy [39].
The manual outlines how SL is different to CBT and which
interventions are prohibited such as offering explanations
for symptoms, eliciting symptom information or changes,
suggesting explicit coping strategies, interpreting informa-
tion rather than responding reflectively, leading or direct-
ing the client and giving homework assignments or tasks.
The SL therapist manual also includes a description of the
listening skills to be used in SL which are based on the the-
ories and counselling techniques of Carl Rogers [40].
These core skills include asking open questions, active lis-
tening skills such as minimal encouragers, paraphrasing,
empathising, reflecting and summarising. The purpose is
to provide the participant the opportunity to talk and
express themselves in a non-judgemental, safe environ-
ment. The person should experience empathy from the
therapist and feel listened to.
More advanced Rogerian counselling skills such as prob-
lem clarification, accurate understanding and challenging
are not included in the therapist training or manual. The
SL was designed to control for the non-specific effects of
therapy such as warmth and positive regard rather than
being formal counselling therapy per se.
The participant or client manual for SL is a short 7 page
document. It provides brief information about MS and
why Supportive Listening may be beneficial for people
with MS. It also outlines what patients can expect from the
therapy sessions and a timetable for scheduling the meet-
ings.
Missed or postponed sessions
In the case of cancellation or non-attendance at therapy
the nurse-therapist will contact the participant by tele-
phone to ascertain the problem of attendance and will
discuss an appropriate solution. If the session can be rear-
ranged to stay in line with the standard scheduling of ses-
sions it should be rescheduled.
Inevitably there will be times when MS symptoms or
relapse, other sickness, holidays, or unexpected events
interfere with the standard scheduling of sessions such
that therapy exceeds or alters the 10 week window
(described earlier). However, generally therapy should be
completed within a maximum of 12 weeks. In exceptional
circumstances (e.g. the participant experiences a severe
relapse of MS or has a family/personal crisis) timing of
sessions can be discussed with principal investigators and
rearranged. However, a participant will never have more
than the 8 sessions.
Therapy record keeping
Deviations from the standard therapy schedule will be
logged so they can be reported and analysed. Details of
the date and length of each session (and for CBT partici-
pants, the chapters covered and a rating on a scale of 1–10
of homework engagement) will be recorded by the nurse-
therapist.
All therapy sessions will be digitally recorded with permis-
sion from the participant and saved in an encrypted anon-
ymous format. These recordings will be used for ongoing
supervision and to assess treatment fidelity and therapist
effects at the end of the trial.
Informing the participants' health professionals regarding 
involvement in the trial
After the first session, the nurse-therapist will write to the
participant's GP and MS service to inform them of the
patient's participation in the trial. For CBT patients this
will also include a summary of the assessment made and
the areas that are likely to be concentrated on in the
remaining sessions (discussed and agreed with the partic-
ipant and a copy sent to the participant for their own
records).
Ongoing supervision of nurse-therapists
Two experienced CBT therapists (SR and TC) will super-
vise the CBT and an experienced health psychologist (RM)
will supervise the SL. For the first two months of the trial
each nurse-therapist will have a separate CBT and SL
supervision session once per week. Supervision will be
fortnightly for the rest of the trial. Sessions will be
between 30 – 60 minutes long and may be either by tele-
phone, or face-to-face. At least once every two months the
nurse-therapists will have a face-to-face session. Tape
recordings of a session will be shared with the supervisor
before the sessions and discussed during supervision.
Each nurse-therapist will keep a log of dates and timings
of their supervision sessions. Once per month the super-BMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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visor will check that session documentation has been
properly completed.
Therapeutic fidelity ratings
Fidelity rating for the interventions will occur throughout
the trial in the supervision sessions. In addition, at the end
of the trial a selection of recordings of therapy sessions
will be assessed by an independent experienced clinician
using a modified version of the therapy rating scale [34]
to ensure treatment integrity. Sessions to be rated will be
selected at the end of the therapy part of the trial without
input from nurses and supervisors. Approximately one
third (randomly chosen) will be co-rated by a second rater
in order to establish reliability of ratings.
Table 3: Summary of the content of the CBT manual for adjustment to MS
Chapter 1:
Introduction to adjusting to MS
What is MS and what does adjusting to MS mean?
Factors which have been shown to affect adjustment in MS.
A CBT model of adjusting to MS which includes interactions between thoughts, behavior, biology 
and emotions.
Assessment of current strengths and difficulties.
Chapter 2:
Adapting to living with MS
What do we mean by acceptance?
Strategies for becoming accepting.
Dealing with negative emotions such as sadness, grief, loss, frustration, anger, anxiety, depression, 
shame and embarrassment.
Chapter 3.
Setting goals and problem solving
Exploring values and setting treatment goals where change may be needed across different areas 
of life.
Once problems are identified, developing a stepped approach to problem solving drawing on the 
patient's strengths and support network.
Chapter 4.
Managing symptoms
Helping make the link between symptoms, thoughts and behaviors. May involve a discussion on 
accepting limitations.
The pitfalls of becoming overly symptom focused and avoidant and strategies for managing these.
Understanding MS symptoms, and which symptoms are likely to be a sign of relapse, medication 
side effects, or stress/distress.
Diaries of patterns of rest and activity to see how these may influence symptom experience.
Chapter 5.
How to tackle negative and unhelpful thoughts
Demonstrations of how perceptions of events can influence coping with illness.
Identifying traps or 'errors' in thinking and finding alternatives can help with adjustment and levels 
of distress.
Examples of unhelpful thoughts are covered such as fears about the illness and future, and high 
personal expectations.
Using daily thought records of unhelpful thoughts, challenging these thoughts and coming up with 
alternative thoughts.
Chapter 6.
Improving the quality of your sleep
Basic sleep hygiene including establishing a good sleep/wake routine which encourages natural 
sleep and addressing factors which interrupt sleep.
Goal setting to improve sleep.
Chapter 7.
Managing stress
Exploring skills to call on in times of stress such as distraction, problem solving, relaxation, 
prioritising, saying no and planning.
Goal setting to improve stress management.
Chapter 8.
Managing social relationships
Becoming more assertive.
Managing relationships with care providers.
Getting the right type of support for one's needs and sharing emotions.
Chapter 9.
Preparing for the future
Identifying physical and emotional warning signs of relapse and normalising these.
Developing a future management plan using personal strengths, newly learnt skills and support 
from others in difficult times.BMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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Outcome assessments
Questionnaires (see Table 1) will be completed at base-
line (prior to randomisation), mid-therapy (session 5 of
therapy sessions), post-therapy follow-up (15 weeks after
randomisation), 6 month follow-up (26 weeks after ran-
domisation) and 12 month follow-up (52 weeks after ran-
domisation). All assessments are questionnaire-based.
Data collection will be managed by the trial co-ordinator
who will be blind to treatment allocation. Participants
will be able to choose whether to complete online or
paper-based questionnaires (returned by freepost). Dates
that questionnaires are sent out and received will be
recorded. A reminder phone call or reminder emails will
be used if the questionnaire is not received within two
weeks of send-out. After four weeks another copy of the
questionnaire pack will be reissued.
If participants are unable to complete questionnaires
themselves (e.g. due to relapse) the trial co-ordinator will
go through the questionnaire on the telephone and this
will be logged as such on the trial database. Spouses/part-
ners/friends will not be allowed to complete the question-
naire on the participant's behalf or assist them with
writing their answers. Completed, returned question-
naires will be checked by the trial co-ordinator and partic-
ipants contacted if there is a large amount of missing data.
Primary outcome measures
There are two primary outcomes.
1. The General Health Questionnaire (GHQ) [41] is
designed to measure general levels of distress in peo-
ple in the community and medical settings. The meas-
ure is uncontaminated by the experience of MS related
somatic symptoms and a recent study showed the
GHQ was the most treatment responsive measure of
psychological distress in three discrete MS samples
[42].
2. The Work and Social Adjustment Scale (WSAS) [43]
is a self-report scale of functional impairment attribut-
able to an identified illness, in this case MS. The scale
measures how much MS interferes with a person's
work, home management, social leisure activities, pri-
vate leisure activities, and the ability to form and
maintain close relationships.
Secondary outcome measures
These include quality of life and factors which have been
shown to be related to adjustment outcome in MS and are
key components of our model of adjustment to MS.
1. Quality of life will be measured using the EuroQol
5 (EQ-5D) [44] which is a 5-item composite measure
of mobility, self-care, usual activities, pain/discomfort
and anxiety/depression.
2. Acceptance of illness will be measured using the
Acceptance of Chronic Health Conditions Scale
(ACHC) [45]. This scale assesses acceptance of and
adjustment to change in one's life due to a chronic
health condition (in this case MS).
3. Dysfunctional cognitions will be measured by the
Psychological Vulnerability Scale (PVS) [46]. This
short scale taps maladaptive cognitive responses
which are proposed to promote unhelpful adjustment
to stressors (e.g. perfectionism, need for approval).
Mediators of the treatment effect
In order to gain a clearer idea of the possible mechanisms
and to help refine our CBT model of MS adjustment we
have included a number of measures as possible media-
tors of the treatment effect. These are cognitive behav-
ioural factors which have been demonstrated to be
associated with adjustment outcomes, and/or are
addressed within either or both interventions. We hypoth-
esize that the mediators of improvements in psychologi-
cal well-being (GHQ) will be different to the mediators of
improvements in functional impairment (WSAS).
Mediators of the WSAS
1. Cognitive and behavioural responses to symptoms.
The Cognitive and Behavioural Response to Symp-
toms Questionnaire (CBRSQ) [Moss-Morris, Chalder,
Skerrett & Baldwin, in preparation] is a newly devised
34 item questionnaire which was designed to measure
patients' cognitive and behavioural responses to
symptoms. The subscales of this questionnaire have
been shown to predict a significant amount of the var-
iance in MS related disability and fatigue over and
above EDSS scores, remission status, and mood [47]
2. Illness perceptions will be assessed using the Brief
Illness Perceptions Questionnaire (BIPQ) [48]. This 8
item questionnaire assesses cognitive and emotional
illness representations (e.g. its timeline, conse-
quences, controllability). Across a range of illnesses,
negative illness perceptions are related to worse
adjustment outcomes, whilst changes to illness per-
ceptions may improve adjustment.
Mediators for GHQ
1. Unhelpful beliefs about emotions are measured
using the recently developed Beliefs About Emotions
Scale (BES) [Rimes & Chalder; in preparation]. This 6
item questionnaire measures the extent to which the
person holds unhelpful beliefs about experiencing,
expressing, and controlling emotions.BMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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2. Dysfunctional cognitions (PVS)[46] as described
above under secondary outcomes.
3. Acceptance of illness (ACHC) [45]as described
above.
Moderators of Treatment Improvement
We will also look at two potential moderators of patients'
response to treatment, the therapeutic alliance and per-
ceived social support.
The therapeutic alliance is measured using the Alliance
subscale of the Therapy Competence and Fidelity Rating
scale [34]. Independent raters blind to treatment outcome
will use this scale to rate therapy tapes from each of the
two therapists. The scale includes items including emo-
tional expression by the patient and level of empathy
expressed by the therapist. Items are rated on a 7-point
Likert Rating Scale, with anchors at four points along the
scale [e.g. 'not at all' (1), 'somewhat' (3), 'considerably'
(5) and 'extensively'].
Social support is measured by the Significant Other Scale
(SOS) [49]. We are using a shortened version of this scale
(8 items) where the participant is asked to state one key
support person and then rate desired and received support
in different domains (e.g. practical help and socialising).
In addition to these measures we have included a number
of questions to measure illness severity, progression and
relapse (see Table 1) including the self-reported Expanded
Disability Status Scale (EDSS)[50]. This will allow us to
assess whether there has been any noticeable disease pro-
gression. The self-reported EDSS is a relatively new instru-
ment which allows MS patients to self-report their current
disease status, rather than this being assessed by a neurol-
ogist during a clinical examination. The questionnaire
includes items which relate to mobility, strength, co-ordi-
nation, sensation, bladder, vision, speech, swallowing,
and cognition. Using the responses from these items,
functional system scores are computed and an EDSS score
is assigned to the participant ranging from 0 (no neuro-
logical impairment) to 10 (death from MS). The trial co-
ordinator will review and score each questionnaire, which
is then co-scored by a neurologist specialising in MS in
order to ensure reliability of scoring.
Patients will also be asked to rate their treatment prefer-
ence at the beginning of the trial and their feelings about
treatment efficacy at the end of the trial.
Service use and QALYs
Service use (additional to the CBT intervention or Sup-
portive Listening which will both be centrally recorded)
by patients in both arms of the trial will be measured
using the Client Service Receipt Inventory (CSRI) [51].
This will record health and social service contacts in the
six months prior to baseline assessment, and the periods
prior to 6- and 12-month follow-up interviews. Time lost
from work because of MS-related problems will also be
measured.
The EuroQol (EQ-5D) [44], a 5 item composite measure
which considers mobility, self-care, usual activities, pain/
discomfort and anxiety/depression will be used to assess
quality of life. The EQ-5D will be used to generate quality
adjusted Life Years (QALYs) [52].
Blinding
The trial co-ordinator will administer all quantitative
assessment procedures and will be kept blind to the treat-
ment allocation of participants until final follow-up has
been completed. The trial co-ordinator will not deal with
paperwork that links a participant to their therapy condi-
tion, or be present when any discussions revealing this
information take place. However, if she becomes aware or
suspicious of the treatment condition of any participant
she will log this lapse of blinding on the trial database for
later consideration in a sensitivity analysis. Either way, as
all assessments are by self-report, rather than rated by a
member of the research team, influences of observer
biases are not expected.
Due to the nature of the interventions it is not possible to
blind the principal investigators and nurse-therapists as
they will be delivering and supervising the therapy ses-
sions. It is also not possible to blind participants to treat-
ment allocation. However, the trial is set up as
comparison of two treatments rather than as a treatment
versus control condition. The participant information
presents both treatments as a way of assisting adjustment
to MS with neither treatment being given preference. Dur-
ing statistical analysis the treatment groups will be
assigned a code rather than their name so that the statisti-
cians are unaware what the treatment group code repre-
sents.
Data inputting
Data will be input into a flat SPSS spreadsheet by the trial
co-ordinator. All primary data (GHQ and WSAS) at all
time points will be double entered by an administrator.
This will then be checked for errors and discrepancies,
which will then be corrected by consulting the raw ques-
tionnaire data (paper based or online). A percentage of all
other data inputting will also be double entered to ensure
accuracy. Any follow-up action (e.g. double entry of more
data) will be taken as necessary.
Qualitative interviews
On receipt of completed post-therapy questionnaires,
details of those participants who have consented to take
part in the in-depth interview will be passed to a post-doc-BMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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toral researcher who has not had any involvement in
other aspects of the trial.
Around 15 CBT participants and 15 SL participants will be
interviewed regarding their experiences of therapy. If a
large enough pool of consenting participants is available,
purposive sampling will be employed on the basis of
questionnaire-based reports of therapy satisfaction, per-
ceived improvement, and demographic and illness char-
acteristics.
The interviewer will contact each participant to schedule a
telephone interview and conduct the interview according
to an interview schedule. Questions address expectations
of therapy, experiences of therapy sessions, features of
therapy liked and disliked, and the process of change (or
not) as a result of therapy. Each interview will be audio-
taped or digitally recorded. Interviews will be transcribed
by an administrator, omitting any information that may
compromise confidentiality. Completed recordings and
transcripts will be stored in a locked cabinet (if printed) or
in a password protected file (if digital) for analysis after
the trial has concluded.
Independent monitoring and quality control
A Trial Steering Committee (TSC) including a Data Moni-
toring Group has been set up to monitor the conduct of
the trial. They will provide overall supervision for the trial
and safeguard its integrity. Authority for continuation of
the trial lies with the TSC. The committee includes an
independent chairperson, the lead and principal investi-
gators, the trial co-ordinator, a statistician, a representa-
tive from the MS Society and a patient representative. The
committee will meet at least annually during the trial
period, and more frequently and/or via telephone confer-
ence or email communication if pressing issues arise.
Compliance
The trial will be conducted in compliance with the Decla-
ration of Helsinki, MRC Good Clinical Practice (GCP)
guidance, the Data Protection Act (1998), the National
Research Ethics Service (NRES) approvals, NHS Trust reg-
ulations, and other regulatory requirements as appropri-
ate. The final trial publication will include the items
recommended under the extended CONSORT statement
for randomized trials of nonpharmacologic treatment
[53].
Participant safety
Both CBT and SL are expected to be of low risk to partici-
pants. They are non-invasive talking therapies and similar
interventions have been previously used in chronic illness
populations. If the nurses are concerned about a patient's
safety, particularly if they believe the person may be vul-
nerable to self-harm, they immediately contact one of the
therapy supervisors who will telephone the patients to
assess the severity of the situation. If necessary, a referral
will be made to ensure the patient gets the support they
need.
Adverse events/reactions
Adverse events (AE), adverse reactions (AR), serious
adverse events (SAE) and serious adverse reactions (SAR)
will be defined according to the usual clinical trial defini-
tions. Where these occur they will be recorded on the trial
spreadsheet and reported to the appropriate authorities
and followed up in the standard manner.
Stopping/discontinuation rules
Departures from the trial protocol, changes to the manu-
alized treatments, and breaking of the randomization
code will only occur with the advice of the TSC if it
becomes apparent that a particular treatment arm is caus-
ing a consistent pattern of deterioration, or if there is
another obvious and significant clinical necessity.
Withdrawals from therapy
If a participant expresses the wish to withdraw from the
trial, the nurse-therapist will contact the participant to
ascertain the reason for drop-out if the participant is will-
ing to share this. They will be offered the option of talking
to a principal investigator instead if they wish. If the par-
ticipant considers that they are deteriorating a principal
investigator will contact them and discuss an appropriate
solution.
The nurse-therapist (or principal investigator if they make
contact) should ascertain whether consent is withdrawn
from:
a) further treatment only
b) further treatment and follow-up (questionnaires
plus the in-depth telephone interview)
c) retaining data already collected for use in final anal-
ysis.
The reason for withdrawal (e.g. adverse events, relapse, ill-
ness progression, inability to adhere, inability to attend)
will be communicated to the principal investigator for
that centre as well as the trial co-ordinator who will record
and report this information as appropriate.
If it is felt that a participant should be withdrawn from the
trial this will be discussed with the nurse-therapist, princi-
pal investigator and clinical supervisor. One of the princi-
pal investigators will assess the participant clinically
within a week and arrange appropriate ongoing care. The
nurse-therapist will write to the participant's GP and MS
service to confirm withdrawal from treatment.BMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
Page 14 of 17
(page number not for citation purposes)
Statistical analysis plan
Statistical analysis will be carried out in SPSS and/or Stata
general purpose statistical analysis packages. Mediation
modeling may require use of specialist structural equation
modeling software (e.g. AMOS or M-Plus).
All treatment group comparisons will be carried out on an
intention-to-treat basis, that is subjects will be analyzed in
the group to which they were randomized irrespectively of
the treatment received. The primary and secondary longi-
tudinal outcomes will be analyzed using linear mixed
modeling. In these models the outcome variable at the
post-treatment time points will be the dependent variable
and baseline values of the outcome variable, centre, time
(post-treatment, 6 M follow-up or 12 M follow-up), group
(CBT or Supportive Listening) and a time × group interac-
tion terms will feature as explanatory variables. To
account for correlation between measures taken on the
same individual at various time points subject-varying
random intercepts and slopes of time will also be
included in the model. Further baseline variables might
be used as explanatory variables, to provide more power-
ful group comparisons if they are found to be predictive of
the outcome variable. As the model fitting will by maxi-
mum likelihood such analyses are valid if missing data
arises at random (MAR). The effect of informative miss-
ingness processes will be explored by means of a formal
sensitivity analysis [54].
We will further investigate whether results were unduly
influenced by patients who have shown marked disease
progression during the trial or who have altered medica-
tion during the trial period. We will also assess the sensi-
tivity of the results to excluding patients who did not
receive a sufficient number of treatment sessions or those
who had low expectations of the therapy they received.
An approach similar to Baron and Kenny's mediation
modeling [55]will be used to explore whether change of
psychological outcomes mediates the path from therapy
to change in MS adjustment. Specifically we will use
instrumental variable methods advocated by Dunn and
colleagues to try and adjust for unobserved confounders
of the path from mediations to outcomes [56,57].
Economic evaluation plan
Service use measured with the CSRI will be combined
with relevant unit costs (e.g. [58]). The cost of the inter-
ventions will be calculated using information on therapist
pay as well as training and supervision costs and over-
heads. Cost comparisons will be made between the two
groups using bootstrapping methods to account for non
normality in the data distribution.
Service cost data will be combined with the primary out-
come measures (GHQ and WSAS) and quality-adjusted
life years (QALYs), generated from the EQ-5D to assess
cost-effectiveness. If the intervention has lower costs and
better outcomes then it will be 'dominant'. In the event of
the intervention having higher service costs and better
outcomes, cost-effectiveness will be assessed using incre-
mental cost-effectiveness ratios. To address uncertainty in
cost and outcome differences we will use cost-effective-
ness planes (CEPs) which will show the probability of the
intervention being (i) cost-saving and more effective, (ii)
cost-saving and less effective, (iii) cost-increasing and
more effective and (iv) cost-increasing and less effective.
Cost-effectiveness acceptability curves (CEACs) will be
generated to show the probability that the intervention is
cost-effective for different values placed on a unit
improvement in the GHQ/WSAS or one extra QALY
gained. CEPs will involve producing a large number of
cost-outcome combinations using bootstrap methods and
plotting these on a plane where one axis represents incre-
mental costs and the other incremental outcome. CEACs
will be generated by computing 'net benefits' for each par-
ticipant (defined as the monetised value of outcome
minus service costs). The value of a unit improvement in
outcome is unknown and therefore a range of values will
be used resulting in a number of different net benefits for
each participant. Regression analyses will be used to esti-
mate the difference in net benefits between the two arms
for each value placed on a unit improvement in outcome.
Bootstrapped regression coefficients of these differences
will be saved and the proportion that are above zero will
indicate the probability that one arm is more cost-effec-
tive than the other.
Qualitative analysis plan
A thematic analysis of the participants' therapy experience
interviews will be conducted based upon procedures
described by Boyatzis and Joffe and Yardley [59,60]. This
will involve an inductive approach whereby transcripts
are coded in order to develop conceptual categories which
describe salient themes in the data. Elements of grounded
theory practice [61,62] will also be incorporated; constant
comparison, "in vivo" coding, attention to discrepant
cases and memoing. Once all transcripts are coded and a
comprehensive coding manual has been developed and
refined we will inspect the data for patterns and relation-
ships in the themes within and between the two therapy
groups.
Reporting and Dissemination
A number of publications are expected from this trial
including:
￿ Main outcome paper
￿ Economic analysis-costs/benefits
￿ Qualitative analysis of patient feedback and experiencesBMC Neurology 2009, 9:45 http://www.biomedcentral.com/1471-2377/9/45
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￿ Predictors of treatment outcome
￿ Mechanisms of change during therapy
￿ Cross-sectional study of factors involved in adjustment
from baseline data
We expect to present the findings at various scientific
forums including MS specific and neurology conferences,
health and clinical psychology conferences, and behav-
ioural medicine meetings. We will also report back to our
funder the MS Society and patient led meetings such MS
Life. A lay summary of the results will be sent to trial par-
ticipants.
Study status
The trial opened to recruitment in January 2008. Enrol-
ment and the therapy interventions will continue until
early 2009. Throughout 2009 follow-up assessments of
participants will be conducted. Results will be analyzed
and reported in 2010.
Discussion
To our knowledge this is the first RCT to look specifically
at assisting with broadly defined psychological adjust-
ment in the early stages of the MS. The relatively inclusive
eligibility criteria for this trial mean that we are offering
therapy to a group of patients who would not otherwise
routinely have any formal psychosocial interventions, but
who nonetheless are faced with considerable adjustment
challenges.
This trial will answer important questions about the effi-
cacy of an 8 session manualized CBT treatment in reduc-
ing distress and MS-related social and role impairment as
well as a number of secondary outcomes. It has a relatively
long follow-up period (12 months) which allows for the
assessment of both short and longer-term effects of the
interventions. The trial will also provide important data
regarding the cost-effectiveness of both interventions and
their acceptability to patients. The trial is also set up in
such a way to study mediators of change during therapy
and therefore shed light on the process of adjustment and
the important factors involved.
If the CBT (or indeed the SL) is an efficacious and cost-
effective intervention for assisting with adjustment to MS,
the fact that it has been manualized and the details of
training, supervision and therapy delivery are intricately
described means that it should be straightforward to rep-
licate on a larger scale. The use of general nurses as thera-
pists in this trial is a significant advantage. If therapy can
be successfully learned and delivered by general nurses
with no prior experience of psychological interventions, it
suggests that it would not be necessary to employ health
professionals with high-level training in clinical psychol-
ogy (who are in short supply and expensive to services) to
deliver adjustment interventions to those with MS.
Indeed, they could potentially be offered by health profes-
sionals who are already working with MS patients in the
NHS (e.g. specialist MS nurses and occupational thera-
pists). Furthermore, the use of telephone contact for the
majority of the therapy sessions means that the interven-
tion could be delivered in a flexible way that could reach
more patients. Mobility difficulties and other disabling
and unpredictable symptoms might be significant barriers
for people with MS accessing face-to-face services.
The trial is set up to be methodologically robust and to
conform to best practice for the conduct and reporting of
RCTs. We have taken care to address key sources of bias;
the manualized therapies are subject to ongoing supervi-
sion to ensure therapy fidelity and this will also be
checked post-therapy by independent raters. The assess-
ments of patient outcomes are self-reported and collected
by the trial co-ordinator who is blind to treatment alloca-
tion and uninvolved in therapy delivery. The CBT is being
exposed to a stringent test of it's efficacy since it is being
compared to a potentially therapeutic intervention, SL.
Although the SL is designed to control for non-specific
therapeutic effects such as of the considerable time and
attention from an interested and caring health profes-
sional, it is based on principles of counseling which
allows patients to explore and work through issues is a
non-directive format.
The saMS trial benefits from patient user input from the
early stages of therapy design and manual development,
right through to the in depth evaluation of the therapy
sessions. The use of qualitative methods alongside the
RCT means that the voice of those who would be using the
intervention has been considered during both the design
and evaluation of the therapy. This qualitative data will be
particularly important in guiding any changes to the ther-
apy format.
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